The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

• Status: Unknown status
• Trial end date: 2020-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone combined with rituximab or bortezomib regimens in newly diagnosed Waldenström macroglobulinemia patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital
• Treatments: BB 1101; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Rituximab

Criteria

Inclusion Criteria:

1. aged >=18 years

2. diagnosed with LPL/WM

3. untreated or mild treated without standard regimens,especially untreated with rituximab and/or bortezomib

4. symptom patients

5. with life-expectancy more than 3 months.

Exclusion Criteria:

1. diagnosed with other malignancies outside B-NHL within one year(including active center neural system lymphoma)

2. transformed lymphoma

3. liver or renal function lesion unrelated to lymphoma

4. serious complications such as uncontrolled diabetes,gastric ulcer or other serious angiocardiopathy determined by the physician

5. HIV positive or active HBV infection or other uncontrolled systematic infection

6. clinical central nervous dysfunction

7. serious surgery within 30 days

8. pregnancy or baby nursing period or un-contracepted child-bearing period woman; 9. allergy to the trail drugs.